Schrodinger (SDGR)
(Delayed Data from NSDQ)
$20.09 USD
-0.39 (-1.90%)
Updated Aug 21, 2024 04:00 PM ET
After-Market: $20.10 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
SDGR 20.09 -0.39(-1.90%)
Will SDGR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SDGR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SDGR
Compared to Estimates, Schrodinger (SDGR) Q2 Earnings: A Look at Key Metrics
Schrodinger, Inc. (SDGR) Reports Q2 Loss, Tops Revenue Estimates
SDGR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Omnicell (OMCL) Expected to Beat Earnings Estimates: Should You Buy?
Earnings Preview: Schrodinger, Inc. (SDGR) Q2 Earnings Expected to Decline
Schrodinger, Inc. (SDGR) Reports Q1 Loss, Misses Revenue Estimates
Other News for SDGR
Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schrodinger to Present at Morgan Stanley Global Healthcare Conference
AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD
Nvidia-backed Recursion to acquire Exscientia in all-stock deal
Schrodinger: More Drug Discovery Validation